Fig. 4: Outcomes across quartile-based categories of neutrophil-to-lymphocyte ratio (NLR) and tumor mutational burden (TMB). | Nature Communications

Fig. 4: Outcomes across quartile-based categories of neutrophil-to-lymphocyte ratio (NLR) and tumor mutational burden (TMB).

From: Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

Fig. 4: Outcomes across quartile-based categories of neutrophil-to-lymphocyte ratio (NLR) and tumor mutational burden (TMB).

Heat maps of hazard ratios (HRs) for a overall survival and b progression-free survival, and heat maps of odds ratios (ORs) for c response and d clinical benefit based on 16 within cancer type quartile-based categories of NLR and TMB. HRs were calculated with Cox proportional hazard regression. ORs were calculated with logistic regression.

Back to article page